Effect of Aging on Human Mesenchymal Stem Cell Therapy in Ischemic Cardiomyopathy Patients

• Published in: Journal of the American College of Cardiology Vol. 65; no. 2; pp. 125 - 132
• Main Authors: Golpanian, Samuel, El-Khorazaty, Jill, Mendizabal, Adam, DiFede, Darcy L., Suncion, Viky Y., Karantalis, Vasileios, Fishman, Joel E., Ghersin, Eduard, Balkan, Wayne, Hare, Joshua M.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 20.01.2015; Elsevier Limited
• Subjects: Adult; Age; Aging; Cardiology; Cardiomyopathy; Cardiovascular; Cardiovascular disease; Cells, Cultured; Clinical trials; Confidence intervals; Female; Heart attacks; Heart failure; Hispanic Americans; Humans; infarct size; ischemic heart disease; Male; Mesenchymal Stem Cell Transplantation - methods; Mesenchymal Stromal Cells - cytology; Middle Aged; Myocardial Ischemia - physiopathology; Myocardial Ischemia - therapy; Older people; Quality of Life; Statistical methods; Stem cells; Transplantation, Autologous; Treatment Outcome; Ventricular Remodeling - physiology; TESI; heart failure; EF; hMSC; CI; ischemic heart disease; ESV; LV; infarct size; ICM; MLHFQ; EDV; MI; MSC; 6MWD; ejection fraction; myocardial infarction; end-diastolic volume; left ventricular; human mesenchymal stem cell; mesenchymal stem cell; 6-min walk distance; end-systolic volume; transendocardial stem cell injection; ischemic cardiomyopathy; confidence interval; Minnesota Living With Heart Failure Questionnaire

The role of patient age in the efficacy of mesenchymal stem cell (MSC) therapy in ischemic cardiomyopathy (ICM) is controversial. This study sought to determine whether the therapeutic effect of culture-expanded MSCs persists, even in older subjects. Patients with ICM who received MSCs via transendo...